Hypothesis

A daily regimen that pairs a low‑dose racetam (piracetam 800 mg), an adaptogen extract (Bacopa monnieri 150 mg standardized to 20 % bacosides), and a synthetic peptide (Selank 250 µg intranasal) will produce a greater improvement in working memory and executive function than any single agent or placebo, mediated by concurrent up‑regulation of acetylcholine‑synthesizing enzymes, down‑regulation of cortisol‑induced LTP impairment, and increased BDNF release.

Mechanistic Rationale

• Piracetam enhances neuronal membrane fluidity and increases choline acetyltransferase activity, raising acetylcholine synthesis Piracetam mechanism.
• Bacopa monnieri attenuates HPA‑axis reactivity, lowering cortisol levels that otherwise suppress hippocampal long‑term potentiation Bacopa stress modulation.
• Selank stimulates BDNF transcription via glucocorticoid‑receptor antagonism and promotes TrkB signaling, supporting synaptic plasticity Selank BDNF effect. When combined, the racetam primes cholinergic transmission, the adaptogen removes a glucocorticoid brake on plasticity, and the peptide supplies neurotrophic support, creating a permissive environment for synergistic cognitive enhancement.

Predictions & Testable Outcomes

1. Primary cognitive outcome – Participants receiving the triple combination will show a minimum 0.5‑standard‑deviation advantage on the Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory task after 8 weeks versus placebo and each monotherapy.
2. Biomarker mediation – The cognitive gain will correlate with (a) increased plasma choline acetyltransferase activity, (b) decreased serum cortisol AUC, and (c) elevated serum BDNF levels.
3. Falsifiability – If the combination does not outperform the best single agent by at least 0.3 SD on the primary cognitive measure, or if biomarker changes do not mediate the effect (mediation analysis indirect effect p > 0.05), the hypothesis is refuted.

Proposed Experimental Design

• Design: Double‑blind, placebo‑controlled, 5‑arm parallel trial (placebo, piracetam alone, Bacopa alone, Selank alone, triple combination).
• Participants: 120 healthy adults aged 25‑45, stratified by baseline working memory score.
• Duration: 8 weeks treatment, 4‑week washout, crossover optional for safety.
• Assessments: CANTAB SWM and Rapid Visual Information Processing at baseline, week 4, week 8; blood draws for AChE activity, cortisol, BDNF at same timepoints.
• Analysis: Mixed‑effects models for cognition; mediation analysis (bootstrapped 5 000 samples) to test biomarker pathways.

Potential Confounds & Mitigation

• Expectancy effects controlled via identical‑appearing capsules and nasal spray.
• Circadian cortisol variation addressed by sampling at 08:00 h each visit.
• Adverse events monitored; Selank dose chosen below threshold for immunomodulatory effects.

This protocol offers a clear, falsifiable test of whether simultaneous cholinergic priming, stress‑axis attenuation, and neurotrophic support yields cognition benefits exceeding the sum of their parts.